Q-omics provides the consensus-scored PCDHB10 profile across patient tissues and cancer cell-line models. PCDHB10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PCDHB10 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PCDHB10 RNA expression shows 16,466 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where PCDHB10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHB10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHB10 survival associations across molecular data types. PCDHB10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHB10 RNA expression–survival associations across cancer types. High PCDHB10 expression shows unfavorable associations in BLCA, BRCA, LUAD and CESC, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PCDHB10 RNA expression.
This table summarizes PCDHB10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PCDHB10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHB10 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, LIHC, KIRP and LUSC. The KIRC box plot shows higher PCDHB10 RNA expression in tumor versus normal tissue (log2 FC = +1.632, t-test p < 0.001).
This table shows molecular features associated with PCDHB10 in patient tissues and cancer cell lines. In patient samples, PCDHB10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHB10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
